Quigley Corp. said Thursday its herpes treatment was not effective in treating infections of the eye in an animal model, but that the drug maker's Quigley Pharma unit will pursue other uses for the treatment.

The company said animal tests to gauge the effectiveness of QR-435 against Herpes Keratitis, when the herpes simplex virus infects the eye, showed that the treatment did not remain in the eye long enough to penetrate the cells to get to the virus. The treatment has eliminated the virus on direct contact in other studies.

Quigley said it will continue developing the compound to treat respiratory viruses. The compound has also been shown to have an effect against influenza viruses, such as the H5N1 strain of the bird flu.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP